Role of Na+/K+-stimulated adenosine triphosphatase in the action of dopaminergic-D2 receptors of the liver in rats

1987 ◽  
Vol 7 (11) ◽  
pp. 839-842 ◽  
Author(s):  
Abdulrahim Abu-Jayyab ◽  
Ahmed Mahgoub
Keyword(s):  
Atpase Activity ◽  
Receptor Antagonist ◽  
Dopamine Receptor ◽  
Inhibitory Activity ◽  
Receptor Agonist ◽  
Adenosine Triphosphatase ◽  
D2 Receptors ◽  
Dopamine Receptor Agonist ◽  
Dopamine Receptor Antagonist

The dopamine receptor agonist, bromocriptine, in a dose of 10 mg/kg i.p. for 14 days, in rats caused a significant increase in liver Na+/K+-ATPase activity, whereas sulpiride, a dopamine receptor antagonist, in a dose of 10 mg/kg, i.p. for 14 days, in rats, caused a significant decrease in liver Na+/K+-ATPase activity. Injection of bromocriptine and sulpiride simultaneously in a group of rats, under the same conditions and using the same doses caused a complete block of both stimulatory activity of bromocriptine and inhibitory activity of sulpiride on liver Na+/K+-ATPase activity. It is suggested that Na+/K+-ATPase may have a role in the action of dopaminergic-D2 receptors.

Lisuride, a Dopamine Receptor Agonist With 5-HT2B Receptor Antagonist Properties

2006 ◽  
Vol 29 (2) ◽  
pp. 80-86 ◽  
Author(s):  
C. Hofmann ◽  
U. Penner ◽  
R. Dorow ◽  
H. H. Pertz ◽  
S. J??hnichen ◽  
...  
Keyword(s):  
Receptor Antagonist ◽  
Dopamine Receptor ◽  
Receptor Agonist ◽  
Dopamine Receptor Agonist

scholarly journals Study of the Role of Dopamine Receptors in Streptozotocin-Induced Depressive-Like Behavior Using the Forced Swim Test Model

2017 ◽  
Vol 7 ◽  
pp. e954
Author(s):  
Afshin Roostaei ◽  
Gholamhassan Vaezi ◽  
Mohammad Nasehi ◽  
Ali Haeri-Rohani ◽  
Mohammad-Reza Zarrindast
Keyword(s):  
Receptor Antagonist ◽  
Dopamine Receptors ◽  
Dopamine Receptor ◽  
Forced Swim Test ◽  
Male Rats ◽  
Test Model ◽  
Dopamine Receptor Antagonist ◽  
Swim Test ◽  
Forced Swim

Background: Diabetes is one of the most common endocrine diseases characterized by hyperglycemia. It is caused by an absolute or relative insulin deficiency or an insulin function deficiency. It is one of the major risk factors of depression, with the rate of depression in diabetic patients amounting to as high as 30%. This study examined the role of dopamine receptors in streptozotocin (STZ)-induced depressive-like behavior using the forced swim test (FST). Materials and Methods: This study was performed on 56 Wistar male rats. STZ at doses of 30 and 60 mg/kg body weight was administered via intraperitoneal (IP) route to induce diabetes and depression in rats. Thereafter, by using halobenzazepine (SCH23390) (D1 dopamine receptor antagonist) and sulpiride (D2 receptor dopamine receptor antagonist), the role of dopamine receptors in STZ-induced depression was studied. The one-way analysis of variance technique, Tukey’s range test, and t-test were used to analyze the data. The P-value less than 0.05 was regarded as statistically significant. Results: Our study showed that STZ at doses of 30 and 60 mg/kg, two weeks after injection, caused prolonged immobility in FST, indicating depressive-like behavior (P<0.05 and P<0.01, respectively). SCH23390 (0.001 mg/mL/kg) and sulpiride (0.1mg/mL/kg) did not change the variables of depression in animals that received STZ (at doses of 30 and 60 mg/mL/kg) two weeks before (P>0.05). Conclusion: According to our study, STZ has a depressive-like behavior two weeks after injection, and dopamine receptors do not play a role in depression associated with STZ use. [GMJ.2018;7:e954]

Antidepressant-like effect of 17β-estradiol: involvement of dopaminergic, serotonergic, and (or) sigma-1 receptor systems

2008 ◽  
Vol 86 (10) ◽  
pp. 726-735 ◽  
Author(s):  
Ashish Dhir ◽  
S.K. Kulkarni
Keyword(s):  
Receptor Antagonist ◽  
Dopamine Receptor ◽  
Receptor Agonist ◽  
Forced Swim Test ◽  
Sigma 1 Receptor ◽  
Dopamine Receptor Antagonist ◽  
Swim Test ◽  
Sigma 1 ◽  
17Β Estradiol ◽  
Immobility Period

17β-estradiol has been reported to possess antidepressant-like activity in animal models of depression, although the mechanism for its effect is not well understood. The present study is an effort in this direction to explore the mechanism of the antidepressant-like effect of 17β-estradiol in a mouse model(s) of behavioral depression (despair behavior). Despair behavior, expressed as helplessness to escape from a situation (immobility period), as in a forced swim test in which the animals are forced to swim for a total of 6 min, was recorded. The antiimmobility effects (antidepressant-like) of 17β-estradiol were compared with those of standard drugs like venlafaxine (16 mg/kg, i.p.). 17β-estradiol produced a U-shaped effect in decreasing the immobility period. It had no effect on locomotor activity of the animal. The antidepressant-like effect was comparable to that of venlafaxine (16 mg/kg, i.p.). 17β-estradiol also exhibited a similar profile of antidepressant action in the tail suspension test. When coadministered with other antidepressant drugs, 17β-estradiol (5 μg/kg, i.p.) potentiated the antiimmobility effect of subeffective doses of fluoxetine (5 mg/kg, i.p.), venlafaxine (2 mg/kg, i.p.), or bupropion (10 mg/kg, i.p.), but not of desipramine (5 mg/kg, i.p.) or tranylcypromine (2 mg/kg, i.p.), in the forced swim test. The reduction in the immobility period elicited by 17β-estradiol (20 μg/kg, i.p.) was reversed by haloperidol (0.5 mg/kg, i.p.; a D2 dopamine receptor antagonist), SCH 23390 (0.5 mg/kg, i.p.; a D1 dopamine receptor antagonist), and sulpiride (5 mg/kg, i.p.; a specific dopamine D2 receptor antagonist). In mice pretreated with (+)-pentazocine (2.5 mg/kg, i.p.; a high-affinity sigma-1 receptor agonist), 17β-estradiol (5 μg/kg, i.p.) produced a synergistic effect. In contrast, pretreatment with progesterone (10 mg/kg, s.c.; a sigma-1 receptor antagonist neurosteroid), rimcazole (5 mg/kg, i.p.; another sigma-1 receptor antagonist), or BD 1047 (1 mg/kg, i.p.; a novel sigma-1 receptor antagonist) reversed the antiimmobility effects of 17β-estradiol (20 μg/kg, i.p.). Similarly, in mice pretreated with a subthreshold dose of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT, a 5-HT1A serotonin receptor agonist), 17β-estradiol (5 μg/kg, i.p.) produced an antidepressant-like effect. These findings demonstrate that 17β-estradiol exerted an antidepressant-like effect preferentially through the modulation of dopaminergic and serotonergic receptors. This action may also involve the participation of sigma-1 receptors.

Parkinson Disease Treated With a Suspected Dopamine Receptor Agonist

1974 ◽  
Vol 30 (5) ◽  
pp. 383-386 ◽  
Author(s):  
T. N. Chase ◽  
A. C. Woods ◽  
G. A. Glaubiger
Keyword(s):  
Parkinson Disease ◽  
Dopamine Receptor ◽  
Receptor Agonist ◽  
Dopamine Receptor Agonist
Sign in / Sign up

Export Citation Format

Share Document